PHRM30003 Study Guide - Final Guide: Tachycardia, Angiotensin Ii Receptor Type 1, Bradykinin
5 Jun 2018
School
Department
Course
Professor
Drug name
Drug class
Molecular target(s)
Mechanism/Function
Contradiction/AE/Notes
Heart failure & Dysrhythmias
(
5)
Na+ channel blocker
Metoprolol
Carvedilol
Beta AR antagonist
Meto: cardiac beta1
Car: vascular beta1 and
alpha 1
Increase SV
NA,ADR
dobutamine
Beta AR a
gonist
NA/ADR:
alpha
and
beta AR
Do: beta1 AR
selective
Iv, short term support for acute heart failure
AE:
- increase cardiac work, O2 demand
- risk of dysrhythmias
Milrinone
PDE inhibitor
Phosphodies
terase
(PDE)
As for beta AR agonist
K+ channel blocker
Ca2+ channel blocker
Atropine
Unclassified
muscarinic antagonist
Muscarinic R
Inhibit MR
Digoxin (cardiac
glycosides)
Unclassified
Digitalis/Digoxin:
- increase contractility but
- increase risk of dysrhythmia due to
late after-depolarisation
inhibit Na+/K+ ATPase
increase intracellular Na+
decrease extracellular Ca2+
increase Ca2+ in SR
increase Ca2+ release with each action
potential
increase contractility
AE:
At later stage, Ca2+ store cannot refill
dysrhythmia
- GIT
- CNS
- Cardiac: ventricular dysrhythmias
Low therapeutic index
Increase toxicity with
- Low K+
- High Ca2+
- Renal impairment
Oral
Adenosine
Electrolyte
supplements
Unclassified
Nitrates
Preload reduction
(4)
vasodilators
Veins
Furosemide
Frusemide
Preload reduction (4)
Loop diuretics
Loop of Henle
Spironolactone
Preload reduction (4)
Aldosterone-R antagonist
Aldosterone
-
R
Inhibit aldosterone action on cortical and
distal tubules
AE:
- Hyperkalaemia
